Current and Emerging Systemic Therapies for Renal Cell Carcinoma: Clinical Evidence and Guideline Recommendations

Download All
Get up to date on multidisciplinary management of renal cell carcinoma with downloadable slides and an on-demand webcast plus an expert commentary from a live webinar on the most important data from ASCO GU 2022.
Brian A. Costello, MD, MS
Eric Jonasch, MD
Elizabeth R. Plimack, MD, MS

Downloadable Slidesets

Download these slides from a live webinar for the most recent data on the use of adjuvant therapy for nonmetastatic RCC and the optimal first line treatment options for patients with advanced RCC.

Brian A. Costello, MD, MS Released: March 1, 2022

Download these slides from a live webinar for the most recent data on the selection and sequencing of therapy for patients with advanced RCC after progression on first-line therapy.

Elizabeth R. Plimack, MD, MS Released: March 1, 2022

Download these slides from a live webinar for the most recent data on the optimal management of treatment-related adverse events for patients with RCC.

Eric Jonasch, MD Released: March 1, 2022

ClinicalThought

Read this commentary on expert responses to questions asked by healthcare professionals during a live webinar on current and emerging adjuvant therapies for patients with localized renal cell carcinoma.

Brian A. Costello, MD, MS Eric Jonasch, MD Elizabeth R. Plimack, MD, MS Released: April 13, 2022

Get up to date on treatment of metastatic renal cell carcinoma with this commentary featuring expert responses to questions asked by healthcare professionals during a live webinar.

Brian A. Costello, MD, MS Eric Jonasch, MD Elizabeth R. Plimack, MD, MS Released: April 13, 2022
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
NCCN Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Exelixis, Inc.
Merck Sharp & Dohme Corp.
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings